It has been proposed that the inhibition of SGLT2 (a transporter for glucose re-absorption in the kidney) can increase glucose excretion in the urine and thereby reduce hyperglycemia for the treatment of type-2 diabetes [12], [13]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.